Voices
HARMONi-6 Demonstrates Significant Overall Survival Benefit in First-Line Squamous NSCLC- Akeso Biopharma
Akeso Biopharma

HARMONi-6 Demonstrates Significant Overall Survival Benefit in First-Line Squamous NSCLC- Akeso Biopharma

Akeso Biopharma shared a post on LinkedIn about a recent article by Zhiwei Chen et al, published in The Lancet:

“HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC.

The Lancet Group published.

34% Reduction in Risk of Death
OS HR = 0.66, P = 0.0017
Median OS: 27.9 mo vs 23.7 mo

Consistent benefits across all subgroups:

  • PD-L1 TPS ≥1%: HR=0.68 | TPS <1%: HR=0.64
  • ≥3 metastatic sites: HR=0.47 | Liver mets: HR=0.69

First global Phase III in sq-NSCLC to achieve dual OS and PFS superiority vs PD-1 plus chemo.”

Title: Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial

Authors: Zhiwei Chen, Fang Yang, Zhou Jiang, Longhua Sun, Lin Wu, Zhengxiang Han, Yun Fan, Yanqiu Zhao, Xingya Li, Haipeng Xu, Xiangjiao Meng, Ying Liu, Zhiye Zhang, Hui Luo, Xuelei Ma, Xuezhen Ma, Qin Shi, Zhongmin Zhang, Runxiang Yang, Pingli Wang, Pinhua Pan, Xiaohong Ai, Jie Li, Xingxiang Pu, Zhiwu Wang, Jian Fang, Ming He, Yong He, Shuliang Guo, Juan Li, Hongbiao Wang, Junqiang Zhang, Qian Chu, Xuewen Liu, Shenpeng Ying, Hongcheng Wu, Hongmei Sun, Yinghua Ji, Ming Zhou, Chao Cao, Kejing Tang, Zhengguo Li, Dairong Li, Zhihong Zhang, Jie Li, Jianya Zhou, Hongzhong Yang, Yingying Du, Hui Yang, Jian Shi, Hualin Chen, Wenting Li, Dongmei Lu, Mingxiu Hu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Shun Lu

Read the Full Article on The Lancet

HARMONi-6 Demonstrates Significant Overall Survival Benefit in First-Line Squamous NSCLC- Akeso Biopharma

More posts about Akeso Biopharma.

 

 

Akeso Biopharma Baiyong Li cancer Chao Cao Dairong Li Dongmei Lu Fang Yang Haipeng Xu Hongbiao Wang Hongcheng Wu Hongmei Sun Hongzhong Yang Hualin Chen Hui Luo Hui Yang Jian Fang Jian Shi Jianya Zhou Jie Li Juan Li Junqiang Zhang Kejing Tang LANCET group Lin Wu Longhua Sun Michelle Xia Ming He Ming Zhou Mingxiu Hu OncoDaily Oncology Pingli Wang Pinhua Pan Qian Chu Qin Shi Runxiang Yang Shenpeng Ying Shuliang Guo Shun Lu Wenting Li Xiangjiao Meng Xiaohong Ai Xingxiang Pu Xingya Li Xuelei Ma Xuewen Liu Xuezhen Ma Yanqiu Zhao Ying Liu Yinghua Ji Yingying Du Yong He Yun Fan Zhengguo Li Zhengxiang Han Zhihong Zhang Zhiwei Chen Zhiwu Wang Zhiye Zhang Zhongmin Maxwell Wang Zhongmin Zhang Zhou Jiang